03:00 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price by $12 to $69 supported by a forward P/E of 34.5x our 2026 EPS estimate, compared to BAM's three-year historical average of 32.3x. The premium is supported by the company executing across all business segments in the ALT industry. Given our previous outlook was too optimistic, we are reducing our EPS estimates in 2025 by $0.12 to $1.60 and 2026's by $0.10 to $1.90 per share. Our premium valuation for BAM compared ALT peers that trade in the 20x range is justified by the company's scale and diversified investments and performance track record.